Cargando…

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab

INTRODUCTION: Elevated type I interferon (IFN) response gene (IRG) expression has proven clinical relevance in predicting rituximab non-response in rheumatoid arthritis (RA). Interference between glucocorticoids (GCs) and type I IFN signaling has been demonstrated in vitro. Since GC use and dose are...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Tamarah D, Vosslamber, Saskia, Blits, Marjolein, Wolbink, Gertjan, Nurmohamed, Mike T, van der Laken, Conny J, Jansen, Gerrit, Voskuyl, Alexandre E, Verweij, Cornelis L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416246/ https://www.ncbi.nlm.nih.gov/pubmed/25889713 http://dx.doi.org/10.1186/s13075-015-0564-y

Ejemplares similares

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters
por: de Jong, Tamarah D., et al.
Publicado: (2016)

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
por: Raterman, Hennie G, et al.
Publicado: (2012)

Moving towards personalized medicine in rheumatoid arthritis
por: de Jong, Tamarah D, et al.
Publicado: (2014)

The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis
por: de Jong, Tamarah D., et al.
Publicado: (2019)

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Combining DNA-microarray data in systemic lupus erythematosus
por: Verweij, Cornelis L, et al.
Publicado: (2011)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis
por: Agca, Rabia, et al.
Publicado: (2021)

Prednisone/rituximab: COVID-19: case report
Publicado: (2021)

Prednisone/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Eptacog-α/prednisone/rituximab: No response: case report
Publicado: (2021)

First in man study of [(18)F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis
por: Verweij, Nicki J. F., et al.
Publicado: (2020)

Methotrexate/prednisone/rituximab: COVID-19 pneumonia: 3 case reports
Publicado: (2021)

Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET
por: Verweij, Nicki, et al.
Publicado: (2022)

Variability in quantitative analysis of atherosclerotic plaque inflammation using (18)F-FDG PET/CT
por: Lensen, Karel-Jan D. F., et al.
Publicado: (2017)

The folate receptor β as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis
por: Chandrupatla, Durga M. S. H., et al.
Publicado: (2018)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
por: van Baarsen, Lisa G. M., et al.
Publicado: (2008)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Prednisone and Prednisolone in the Treatment of Rheumatoid Arthritis
por: Montgomery, D. A. D.
Publicado: (1957)

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis
por: Ramwadhdoebe, Tamara H, et al.
Publicado: (2019)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Dexamethasone/prednisone/rituximab: Prolonged SARS-CoV-2 infection and off-label use: case report
Publicado: (2022)

Systematic Review: Targeted Molecular Imaging of Angiogenesis and Its Mediators in Rheumatoid Arthritis
por: Khodadust, Fatemeh, et al.
Publicado: (2022)

Quantitative Assessment of Arthritis Activity in Rheumatoid Arthritis Patients Using [(11)C]DPA-713 Positron Emission Tomography
por: Yaqub, Maqsood, et al.
Publicado: (2020)

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
por: Saffari, Fatemeh, et al.
Publicado: (2022)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Mycophenolate/prednisone/rituximab: Disseminated Varicella zoster virus infection complicated by acute respiratory distress syndrome: case report
Publicado: (2020)

Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome
por: Schijvens, Anne M., et al.
Publicado: (2018)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Go, Se‐Il, et al.
Publicado: (2016)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Sustained Macrophage Infiltration upon Multiple Intra-Articular Injections: An Improved Rat Model of Rheumatoid Arthritis for PET Guided Therapy Evaluation
por: Chandrupatla, Durga M. S. H., et al.
Publicado: (2015)

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis
por: Krasselt, Marco, et al.
Publicado: (2016)

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial
por: Hartman, Linda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ucbcrdt50mrudrunorjm6bl2kh